• when accuracy means everything

    when accuracy means everything

  • complete panel of diagnostics

    complete panel of diagnostics

  • at the end of every test is a patient

    at the end of every test is a patient

  • early detection improves outcomes

    early detection improves outcomes

  • your laboratory next door

    your laboratory next door

The total solution in autoimmunity™

Immco Diagnostics develops and distributes autoimmune disease diagnostics and reagents to labs worldwide. We offer laboratory testing of autoimmune diseases for the US healthcare market. Our contract research organization supports clinical research trials for pharmaceutical and biotech clients. Immco assay development led to the first immunofluorescence assay for diagnosing celiac disease and the first Western blot assay for autoimmune hearing loss. Our new line of enhanced ELISA assays provides standardized calibration systems, an industry first. We are continually expanding our product offering. So come visit us often as we focus on our principal mission at Immco—providing the total solution in autoimmunity™.

Products

Products

Immco offers a wide selection of autoimmune diagnostics under our leading brands: ImmuGlo™,ImmuLisa™, and ImmuBlot™

Immunofluorescence microscopy is the cornerstone of autoimmune diagnostics at Immco. As a leader in developing IFA (indirect immunofluoresence assays), we offer a full range of IFA products for detecting autoimmune disease. ImmuGlo™ is supported with flexible configurations and high quality reagents that ensure reproducibility and ease of use.

Immco ELISAs (enzyme linked immunosorbent assays) feature highly accurate qualitative and quantitative antibody detection for proper diagnosis of autoimmune disorders. Introduction of our new ImmuLisa™ Enhanced assays features industry leading advantages:

  • Antigens are selected and presented in a highly purified form for the highest accuracy
  • Standardized component sets and methods provide greater reproducibility
  • Optimal detection systems yield enhanced sensitivity and specificity
  • Optimal design for performance on all major automated ELISA platforms
  • Choice of single or multiple point calibration for greater flexibility
  • Longer shelf life up to 18 months to support laboratory needs.

Immco's ImmuBlot™ uses Western blot assay methodology to provide highly sensitive, qualitative detection of autoantibodies in serum. ImmuBlot™ assays feature leading reliability and are primarily used to identify specific analytes or serve as confirmatory tests.

Lab Services

Lab Services

Immco Reference Lab Services, specializing in autoimmune diseases and immunopathology, provides laboratory testing with over 200 cutting edge diagnostics using direct and indirect immunofluorescence (IFA), enzyme linked immunosorbent assays (ELISA), Western blot detection methods and biopsy studies to support healthcare practitioners across a wide clinical spectrum. We provide histopathology and serology for oral diagnostics, autoimmunology and immunogenetics for common autoimmune diseases such as lupus, rheumatoid arthritis, celiac disease, polymyositis, systemic sclerosis, and thyroiditis, as well as the less prevalent autoimmune disorders. Our laboratory testing includes:

  • Connective tissue disorder diagnostics for systemic lupus erythematosus, scleroderma, rheumatoid arthritis, and vasculitis
  • Gastrointestinal disease diagnostics including celiac disease, inflammatory bowel disorders, pernicious anemia and autoimmune gastritis
  • Liver disease diagnostics such as autoimmune hepatitis and primary biliary cirrhosis
  • Vesiculo-bullous disorder diagnostics for pemphigus, pemphigoid, and epidermolysis bullosa acquisita
  • Endocrine disorder diagnostics including Type 1 diabetes, Graves' disease, Hashimoto's thyroiditis, Addison's disease and premature ovarian dysfunction
  • Neurological diagnostics for peripheral neuropathies, paraneoplastic syndromes, Guillain-Barré Syndrome, Miller Fisher Syndrome, neuropsychiatric lupus, and myasthenia gravis
  • Cardiovascular diagnostics for patients at risk for atherosclerosis, myocarditis, and cardiomyopathy.

Featured Product

Clinical Specialties

Line Immunoassay (LIA) products

IMMCO is pleased to announce the introduction of a proprietary technology and format for detection of 68kD antibodies to a 68kD heat shock protein associated with autoimmune Sensorineural Hearing Loss (SNHL). Future LIA products with planned availability throughout 2012 will include tests for Myositis, ANA, Liver and Gastro antibodies.

Autoimmune hearing loss is a debilitating condition that affects approximately 15,000 individuals per year, with approximately 4,000 cases reported annually in the United States. The new ImmcoStripe™ hsp-70 Antibody LIA detects antibodies associated with autoimmune hearing loss and is manufactured using highly purified rhsp-70 antigen for a high degree of sensitivity and reliability.

New ImmcoStripe™ hsp-70 Antibody LIA assay is the first in a series of new LIAs to be developed by IMMCO. This assay features:

 High specificity for SNHL
 Clear visual reactions
 Positive, negative and indeterminate results vs. the cut-off line
 Easier to read format and greater reproducibility than Western Blot
 Control lines ensuring that specimen, conjugate and substrate have been added
 Complete traceability with user friendly multisession reporting
 Proprietary technology

Order Information
Order fulfillment will occur within one week of order. Orders can be placed as follows:

ImmcoStripe™ hsp-70 LIA Catalog #6001

Contact: Immco Customer Service at (800)537-8378 or via e-mail to orders@immco.com

Marketing Brochures
Literature is available and product inserts ready for download from our website. These materials can also be sent by calling IMMCO Customer Service at the phone or e-mail listed above.

Licensure
New ImmcoStripe™ hsp-70 Antibody LIA Assay is CE marked, has Health Canada licensure and comes with multi-lingual product inserts. The product is For Research Only in the US. The combination of ImmcoStripe™ hsp-70 Antibody LIA Assay diagnostics, along with the complete line of IMMCO products provide the total solution in autoimmunity™.

News

IMMCO Diagnostics’ Kishore Malyavantham, Ph.D., Director of Science and Technology, spoke at the “China Autoimmune Liver Conference” held in Beijing last month.  Dr. Malyavantham’s presentation titled “Autoantibodies in the Diagnosis and Management of Liver Diseases”, discussed the classic and the most recent biomarkers related to autoimmune liver diseases and the impact of diagnostic algorithms adopted by leading reference labs in the United States.  “This is an exciting time at IMMCO as we are pushing beyond our traditional international markets and expanding into Asia with growing partnerships in both China and India” said Raul Saona, Director of International Sales.
 

Founded in 1971, IMMCO produces autoimmune disease diagnostics and related components.  The company distributes products to laboratories, physicians and other healthcare providers in more than 55 countries, with primary facilities in Amherst, New York and Ontario, Canada.  IMMCO’s lab services division offers testing for autoimmune diseases, immunopathology, and immunogenetics.  IMMCO leverages its products and services division’s wide product offering and years of expertise, IMMCO’s contract research group supports clinical research trials for pharmaceutical and biotech clients.